The "Cerebrospinal Fluid Sink Therapeutic Strategy" in Alzheimer's Disease-From Theory to Design of Applied Systems

被引:9
|
作者
Schreiner, Thomas Gabriel [1 ,2 ,3 ]
Menendez-Gonzalez, Manuel [4 ,5 ,6 ]
Popescu, Bogdan Ovidiu [1 ,7 ,8 ]
机构
[1] Univ Med & Pharm Carol Davila, Fac Med, Bucharest 050474, Romania
[2] Univ Med & Pharm Gr T Popa, Dept Neurol, Iasi 700115, Romania
[3] Gheorghe Asachi Tech Univ Iasi, Fac Elect Engn & Informat Technol, Dept Elect Measurements & Mat, Iasi 700050, Romania
[4] Univ Oviedo, Dept Med, Oviedo 33006, Spain
[5] Hosp Univ Cent Asturias, Dept Neurol, Oviedo 33006, Spain
[6] Inst Invest Sanitaria Principado Asturias, Oviedo 33006, Spain
[7] Colentina Clin Hosp, Neurol Dept, Bucharest 020125, Romania
[8] Victor Babes Natl Inst Pathol, Lab Cell Biol Neurosci & Expt Myol, Bucharest 050096, Romania
关键词
Alzheimer's disease; amyloid-beta; cerebrospinal fluid; therapy; implantable device; clearance; AMYLOID-BETA; MOUSE MODEL; NEPRILYSIN; CLEARANCE;
D O I
10.3390/biomedicines10071509
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alzheimer's disease (AD) is a global health problem, with incidence and prevalence considered to increase during the next decades. However, no currently available effective treatment exists despite numerous clinical trials in progress. Moreover, although many hypotheses are accepted regarding the pathophysiological mechanisms of AD onset and evolution, there are still many unknowns about the disorder. A relatively new approach, based on the amyloid-beta dynamics among different biological compartments, is currently intensely discussed, as it seems to offer a promising solution with significant therapeutic impact. Known as the "cerebrospinal-fluid-sink therapeutic strategy", part of the "three-sink therapeutic strategy", this theoretical model focuses on the dynamics of amyloid-beta among the three main liquid compartments of the human body, namely blood, cerebrospinal fluid, and the (brain) interstitial fluid. In this context, this article aims to describe in detail the abovementioned hypothesis, by reviewing in the first part the most relevant anatomical and physiological aspects of amyloid-beta dynamics. Subsequently, explored therapeutic strategies based on the clearance of amyloid-beta from the cerebrospinal fluid level are presented, additionally highlighting their limitations. Finally, the originality and novelty of this work rely on the research experience of the authors, who focus on implantable devices and their utility in AD treatment.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Proteomic analysis of cerebrospinal fluid in Alzheimer's disease
    Watanabe, A
    Arai, H
    Asada, T
    Washimi, Y
    Endo, H
    Tabira, T
    NEUROBIOLOGY OF AGING, 2004, 25 : S359 - S359
  • [22] Cerebrospinal fluid markers for prediction of Alzheimer's disease
    Zetterberg, H
    Wahlund, LO
    Blennow, K
    NEUROSCIENCE LETTERS, 2003, 352 (01) : 67 - 69
  • [23] Metabolite Profiling of Alzheimer's Disease Cerebrospinal Fluid
    Czech, Christian
    Berndt, Peter
    Busch, Kristina
    Schmitz, Oliver
    Wiemer, Jan
    Most, Veronique
    Hampel, Harald
    Kastler, Juergen
    Senn, Hans
    PLOS ONE, 2012, 7 (02):
  • [24] Cerebrospinal fluid biomarkers for the diagnosis of Alzheimer's disease
    Papassotiropoulos, A
    Maddalena, A
    Gretener, D
    Nitsch, RM
    Hock, C
    LIVING BRAIN AND ALZHEIMER'S DISEASE, 2004, : 17 - 24
  • [25] Cerebrospinal fluid and blood biomarkers in Alzheimer's disease
    Humpel, Christian
    Hochstrasser, Tanja
    WORLD JOURNAL OF PSYCHIATRY, 2011, 1 (01): : 8 - 18
  • [26] Cerebrospinal fluid production in Alzheimer's disease patients
    Religa, D.
    Andreasen, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 318 - 318
  • [27] Plasma and Cerebrospinal Fluid Metals in Alzheimer's Disease
    Quinn, Joseph
    Anekonda, Thimmappa
    Kaye, Jeffrey
    Westaway, Shawn
    Harris, Christopher
    Robinson, Emily
    Ralle, Martina
    NEUROLOGY, 2011, 76 (09) : A229 - A229
  • [28] Trace elements in the cerebrospinal fluid in Alzheimer's disease
    Rao, KSJ
    Shanmugavelu, P
    Shankar, SK
    Devi, RPR
    Rao, RV
    Pande, S
    Menon, RB
    ALZHEIMERS REPORTS, 1999, 2 (06): : 333 - 338
  • [29] Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease
    Khoonsari, Payam Emami
    Haggmark, Anna
    Lonnberg, Maria
    Mikus, Maria
    Kilander, Lena
    Lannfelt, Lars
    Bergquist, Jonas
    Ingelsson, Martin
    Nilsson, Peter
    Kultima, Kim
    Shevchenko, Ganna
    PLOS ONE, 2016, 11 (03):
  • [30] Association of cerebrospinal fluid Neurogranin with Alzheimer's disease
    Wang, Lijun
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2019, 31 (02) : 185 - 191